date,title,source
Oct-23-18,Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics' Lead Drug Candidate VB-111 until October 2033,GlobeNewswire
Nov-13-18,VBL Therapeutics to Report Third Quarter 2018 Financial Results on November 20,GlobeNewswire
Nov-16-18,VBL Therapeutics Presents Results from Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma at the 2018 Society for Neuro-Oncology Annual Meeting,GlobeNewswire
Nov-20-18,"Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates",Zacks
Nov-20-18,Vascular Biogenics: 3Q Earnings Snapshot,Associated Press
Nov-20-18,VBL Therapeutics Announces Third Quarter 2018 Financial Results,GlobeNewswire
Nov-21-18,Edited Transcript of VBLT earnings conference call or presentation 20-Nov-18 1:30pm GMT,Thomson Reuters StreetEvents
Nov-21-18,VBL Therapeutics to Present at the Piper Jaffray 30th Annual Healthcare Conference on November 28,GlobeNewswire
